MA52121A - Traitement et prévention de pré-éclampsie - Google Patents

Traitement et prévention de pré-éclampsie

Info

Publication number
MA52121A
MA52121A MA052121A MA52121A MA52121A MA 52121 A MA52121 A MA 52121A MA 052121 A MA052121 A MA 052121A MA 52121 A MA52121 A MA 52121A MA 52121 A MA52121 A MA 52121A
Authority
MA
Morocco
Prior art keywords
prevention
eclampsia
treatment
eclampsia treatment
Prior art date
Application number
MA052121A
Other languages
English (en)
Inventor
Vries Sijmen De
Bruno Giannetti
Original Assignee
Pharming Intellectual Property Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharming Intellectual Property Bv filed Critical Pharming Intellectual Property Bv
Publication of MA52121A publication Critical patent/MA52121A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA052121A 2018-02-28 2019-02-28 Traitement et prévention de pré-éclampsie MA52121A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18159064 2018-02-28

Publications (1)

Publication Number Publication Date
MA52121A true MA52121A (fr) 2021-06-02

Family

ID=61521416

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052121A MA52121A (fr) 2018-02-28 2019-02-28 Traitement et prévention de pré-éclampsie

Country Status (17)

Country Link
US (2) US20200390872A1 (fr)
EP (1) EP3758739B1 (fr)
JP (1) JP2021515757A (fr)
KR (1) KR20210005549A (fr)
CN (1) CN111818938A (fr)
AU (1) AU2019226355A1 (fr)
BR (1) BR112020017626A2 (fr)
CA (1) CA3092163A1 (fr)
EA (1) EA202092045A1 (fr)
ES (1) ES2982000T3 (fr)
IL (1) IL276905A (fr)
MA (1) MA52121A (fr)
MX (1) MX2020008969A (fr)
PH (1) PH12020551331A1 (fr)
PL (1) PL3758739T3 (fr)
SG (1) SG11202008078QA (fr)
WO (1) WO2019166556A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3895726A1 (fr) 2020-04-17 2021-10-20 Pharming Intellectual Property BV Utilisation d'un inhibiteur d'estérase c1 pour traiter une détresse respiratoire aiguë liée à une infection virale
CA3225079A1 (fr) 2021-07-09 2023-01-12 Bruno Giannetti Utilisation d'un inhibiteur de c1 esterase pour traiter des symptomes lies a une infection virale

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992022320A1 (fr) * 1991-06-14 1992-12-23 Genentech, Inc. Variantes de l'inhibiteur c1 et traitement des reactions inflammatoires avec l'inhibiteur c1
GB9618931D0 (en) 1996-09-11 1996-10-23 Univ London Inositol phosphoglycans for therapeutic use in pre-eclampsia and diabetes
US7067713B2 (en) * 2000-01-31 2006-06-27 Pharming Intellectual Property B.V. C1 Inhibitor produced in the milk of transgenic non-human mammals
CA2398707C (fr) * 2000-01-31 2010-10-26 Pharming Intellectual Property B.V. Inhibiteur de c1 produit dans du lait de mammiferes transgeniques
GB0015625D0 (en) * 2000-06-26 2000-08-16 Univ London Materials and methods relating for the treatment and diagnosis of pre-eclampsia
PT2305301E (pt) * 2002-07-19 2015-04-21 Beth Israel Hospital Métodos de tratamento de pré-eclâmpsia
US20050255114A1 (en) * 2003-04-07 2005-11-17 Nuvelo, Inc. Methods and diagnosis for the treatment of preeclampsia
JP2007500741A (ja) 2003-05-16 2007-01-18 ファーミング・インテレクチュアル・プロパティー・ビー．ブイ． 一時的処置のための短い半減期を有するｃ１インヒビター
DE602005024850D1 (de) * 2004-09-24 2010-12-30 Beth Israel Hospital Verfahren zur diagnose und behandlung von schwangerschaftsskomplikationen
CN105641688B (zh) * 2005-12-21 2020-06-09 法明知识产权股份有限公司 C1抑制剂在预防缺血-再灌注损伤中的应用
PL2380587T3 (pl) 2005-12-21 2018-03-30 Pharming Intellectual Property B.V. Zastosowanie inhibitora C1 do zapobiegania uszkodzeniu niedokrwiennoreperfuzyjnemu
JP6538561B2 (ja) * 2012-10-25 2019-07-03 バイオベラティブ・ユーエスエイ・インコーポレイテッド 抗補体Ｃ１ｓ抗体とそれらの用途
US20150330989A1 (en) * 2012-11-15 2015-11-19 The Brigham And Women's Hospital, Inc. Method and system for diagnosing and treating preeclampsia
DK3290046T3 (en) 2013-03-15 2019-03-18 Shire Viropharma Inc C1-INH COMPOSITIONS AND PROCEDURES FOR PREVENTION AND TREATMENT OF DISEASES ASSOCIATED WITH C1-ESTERASE INHIBITOR LACK
WO2016081889A1 (fr) * 2014-11-21 2016-05-26 Kurt Baekgaard Osther Inhibiteur recombinant de la c1-estérase et utilisation de celui-ci
MA45473A (fr) 2016-04-04 2019-02-13 Shire Human Genetic Therapies Inhibiteur de c1 estérase conjugué et ses utilisations
EP3895726A1 (fr) * 2020-04-17 2021-10-20 Pharming Intellectual Property BV Utilisation d'un inhibiteur d'estérase c1 pour traiter une détresse respiratoire aiguë liée à une infection virale

Also Published As

Publication number Publication date
SG11202008078QA (en) 2020-09-29
CA3092163A1 (fr) 2019-09-06
PH12020551331A1 (en) 2021-09-06
AU2019226355A1 (en) 2020-09-17
ES2982000T3 (es) 2024-10-14
EP3758739B1 (fr) 2024-05-15
JP2021515757A (ja) 2021-06-24
MX2020008969A (es) 2021-02-16
PL3758739T3 (pl) 2024-09-16
WO2019166556A1 (fr) 2019-09-06
US20240285736A1 (en) 2024-08-29
EA202092045A1 (ru) 2020-11-09
EP3758739C0 (fr) 2024-05-15
KR20210005549A (ko) 2021-01-14
US20200390872A1 (en) 2020-12-17
IL276905A (en) 2020-10-29
BR112020017626A2 (pt) 2020-12-22
CN111818938A (zh) 2020-10-23
EP3758739A1 (fr) 2021-01-06

Similar Documents

Publication Publication Date Title
MA45192A (fr) Traitement d'association
MA50056A (fr) Procédés de traitement de tumeur
DK3731772T3 (da) Systems for the treatment of disease states and disorders
DK3743053T3 (da) Anvendelse af cannabinoider i behandling af epilepsi
MA56212A (fr) Compositions et méthodes de traitement du cancer
MA47613A (fr) Compositions et procédés de traitement du cancer
MA47408A (fr) Traitement du cancer
MA46061A (fr) Traitement ascaroside de maladies auto-immunes et inflammatoires
MA52627A (fr) Traitement du cancer
MA47820A (fr) Traitement de la glycogénose de type iii
SG11202103567RA (en) Methods of treatment of inflammatory conditions and associated infections
MA51525A (fr) Traitement de minéraux
MA42999A (fr) Polythérapie pour le traitement de malignités
MA49633A (fr) Agents, utilisations et procédés de traitement
MA42930A (fr) Traitement de maladies neurodégénératives
ZA202000558B (en) Prevention and/or treatment of neurodegenerative disease
EP3428178A4 (fr) Peptide de prévention ou de traitement de maladies inflammatoires et son utilisation
IL277911A (en) Treatment of IGE-mediated allergic diseases
MA52121A (fr) Traitement et prévention de pré-éclampsie
IT201700121764A1 (it) Composizione per il trattamento e/o la prevenzione di patologie neurodegenerative.
DE112020004659A5 (de) Behandlungsanlage und Behandlungsverfahren
MA54932A (fr) Traitement contre le cancer
ZA201906964B (en) Prevention and/or treatment of inflammatory skin disease
DK3229811T3 (da) Forebyggelse og behandling af betændelseslidelser
MA49688A (fr) Procédés de traitement du syndrome myélodysplasique